RXST Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

27.53M

-31.53%

-0.346

+130.81%

30.89M

-18.5%

-0.271

+35.3%

33.05M

-1.75%

-0.259

-10.82%

Estimates Revision

The market is revising Upward the revenue expectations for RxSight, Inc. (RXST) for FY2025, with the revenue forecasts being adjusted by 2.86% over the past three months. During the same period, the stock price has changed by 16.85%.

Revenue Estimates for FY2025

Revise Upward

+2.86%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.71%

In Past 3 Month

Stock Price

Go Up

+16.85%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast RXST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXST is 9.60 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

4 Hold

2 Sell

Hold

Current: 0.000

Low

8.00

Averages

9.60

High

12.00

Current: 0.000

Low

8.00

Averages

9.60

High

12.00

Morgan Stanley

Equal Weight

maintain

$9 -> $10

2025-12-02

Reason

Morgan Stanley

Price Target

$9 -> $10

2025-12-02

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on RxSight to $10 from $9 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.

JPMorgan

Underweight

maintain

$8 -> $9

2025-11-06

Reason

JPMorgan

Price Target

$8 -> $9

2025-11-06

maintain

Underweight

Reason

JPMorgan raised the firm's price target on RxSight to $9 from $8 and keeps an Underweight rating on the shares. The company's Q3 report cleared a low bar but its growth outlook remains uncertain, the analyst tells investors in a research note.

Stifel

Hold

maintain

$8 -> $10

2025-11-06

Reason

Stifel

Price Target

$8 -> $10

2025-11-06

maintain

Hold

Reason

Stifel raised the firm's price target on RxSight to $10 from $8 and keeps a Hold rating on the shares. The quarter was better than feared, with revenue of $30M strongly above the firm's and Wall Street's estimates, the analyst tells investors in a research note. The firm added that it senses the Street's $134M 2026 revenue estimate is in a comfortable place.

UBS

Neutral

downgrade

$16 -> $8

2025-08-08

Reason

UBS

Price Target

$16 -> $8

2025-08-08

downgrade

Neutral

Reason

UBS lowered the firm's price target on RxSight to $8 from $16 and keeps a Neutral rating on the shares following the Q2 earnings report. RxSight's commercial strategy pivot is still under way, and its turnaround depends on improving execution, the analyst tells investors in a research note. The firm lacks conviction in raising assumptions, and needs to see evidence that a turnaround is occurring.

Needham

Buy

downgrade

$22 -> $11

2025-08-08

Reason

Needham

Price Target

$22 -> $11

2025-08-08

downgrade

Buy

Reason

Needham lowered the firm's price target on RxSight to $11 from $22 and keeps a Buy rating on the shares after its Q2 results came in-line with its pre-announcement. RxSight has continued on its commercial pivot, which involves providing more support to its existing accounts in an attempt to drive utilization, though the firm is reducing its price target to reflect a lower multiple, the analyst tells investors in a research note.

Morgan Stanley

Overweight -> Equal Weight

downgrade

$20 -> $9

2025-07-15

Reason

Morgan Stanley

Price Target

$20 -> $9

2025-07-15

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley downgraded RxSight to Equal Weight from Overweight with a price target of $9, down from $20. Morgan Stanley says it doesn't have visibility on RxSight's near-term growth to remain Overweight following the significant slowdown in LDD placements in Q2 as well as a tougher competitive environment, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Rxsight Inc (RXST.O) is -9.28, compared to its 5-year average forward P/E of -27.24. For a more detailed relative valuation and DCF analysis to assess Rxsight Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-27.24

Current PE

-9.28

Overvalued PE

1.34

Undervalued PE

-55.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-26.57

Current EV/EBITDA

-4.19

Overvalued EV/EBITDA

3.00

Undervalued EV/EBITDA

-56.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.09

Current PS

3.41

Overvalued PS

11.68

Undervalued PS

4.50

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RXST News & Events

Events Timeline

No data

News

9.5

14:47 PMGlobenewswire

PinnedRxSight Reports $134.5M Revenue for 2025, Announces CFO Transition

1.0

01-02Globenewswire

RxSight to Present at J.P. Morgan Healthcare Conference on January 13, 2026

1.0

01-02Newsfilter

RxSight to Present at J.P. Morgan Healthcare Conference on January 13, 2026

People Also Watch

Frequently Asked Questions

What is Rxsight Inc (RXST) stock price today?

The current price of RXST is 8.84 USD — it has decreased -7.63 % in the last trading day.

What is Rxsight Inc (RXST)'s business?

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.

What is the price predicton of RXST Stock?

What is Rxsight Inc (RXST)'s revenue for the last quarter?

Rxsight Inc revenue for the last quarter amounts to 30.34M USD, decreased -14.09 % YoY.

What is Rxsight Inc (RXST)'s earnings per share (EPS) for the last quarter?

Rxsight Inc. EPS for the last quarter amounts to -0.24 USD, increased 50.00 % YoY.

What changes have occurred in the market's expectations for Rxsight Inc (RXST)'s fundamentals?

How many employees does Rxsight Inc (RXST). have?

Rxsight Inc (RXST) has 498 emplpoyees as of January 11 2026.

What is Rxsight Inc (RXST) market cap?

Today RXST has the market capitalization of 363.47M USD.